CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 30 enrolled
Drug / intervention
Carvedilol +1 moredrug
Likely dose
Carvedilol 3.125mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01586156
NCT01586156N/ACompleted
CompareCT.gov

Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure

The Cleveland Clinic·interventional·Posted Apr 26, 2012·Updated Dec 5, 2018

In Brief

A clinical study evaluating Carvedilol and placebo for Pulmonary Hypertension. Completed, enrolled 30 participants across 1 site.

Detailed Summary

Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary vasculature leading to elevated pulmonary pressure and right ventricular (RV) dysfunction with heart failure. Measures of RV function are better predictors of mortality and long term outcomes than pulmonary vascular resistance. The interaction between RV function and the pulmonary circulation is not fully understood, but increased after load appears insufficient to explain right heart failure. Yet, all approved PAH therapies target vasodilation of the pulmonary vasculature to lower pressures

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Hypertension
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 26, 2012
Enrollment StartDec 1, 2012
Primary CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 14.2 years ago

Interventions

Carvediloldrug

Group 1 will receive 3.125mg carvedilol twice daily for six months.Group 2 will receive carvedilol in a dose escalation scheme.

placebodrug

Placebo will be taken twice daily for 6 months